Nrf2 activator-25
Nrf2 activator-25 is a Nrf2 activator. Nrf2 activator-25 promotes the dissociation of Nrf2 from Keap1 (with a Kd of 21.3 μM for Keap1), drives Nrf2 nuclear translocation, and increases the production of downstream antioxidant enzymes. Nrf2 activator-25 inhibits apoptosis, ferroptosis and vascular fibrosis, and protects vascular endothelial cells from damage. Nrf2 activator-25 can be used in the research of diabetic vascular diseases.
For research use only. We do not sell to patients.
- Formula: C15H17NO3
- Molecular Weight:259.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Nrf2 activator-25 (Compound 3h) at 20 μM maintains the survival rate of serum- and growth factor-starved human umbilical vein endothelial cells (HUVECs) at 93.61%, with extremely low cytotoxicity[1].
Nrf2 activator-25 (5-20 μM; 6-24 h) concentration-dependently inhibits apoptosis and ferroptosis of HUVECs damaged by ox-LDL, high glucose and CoCl2 after 12 h of treatment[1].
Nrf2 activator-25 (5-20 μM; 6-12 h) concentration-dependently inhibits the expression of ICAM-1 and VCAM-1 in HUVECs damaged by ox-LDL, high glucose and CoCl2[1].
Nrf2 activator-25 (20 μM; 6-24 h) protects HUVECs injured by ox-LDL, high glucose and CoCl2 against mitochondrial membrane potential loss[1].
Nrf2 activator-25 (20 μM; 6-24 h) inhibits ROS accumulation in HUVECs damaged by ox-LDL, high glucose and CoCl2[1].
Nrf2 activator-25 (5-20 μM; 6-24 h) concentration-dependently inhibits lipid peroxidation in HUVECs damaged by ox-LDL, high glucose, and CoCl2, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ox-LDL-injured human umbilical vein endothelial cells (HUVECs)
-
Concentration:5, 10 and 20 μM
-
Incubation Time:6 h
-
Result:Reduced the percentage of apoptotic HUVECs with condensed/fragmented nuclei in a concentration-dependent manner, relative to ox-LDL-only treated cells.
-
Cell Line:high glucose (HG)-injured human umbilical vein endothelial cells (HUVECs)
-
Concentration:5, 10 and 20 μM
-
Incubation Time:24 h
-
Result:Reduced the percentage of apoptotic HUVECs with condensed/fragmented nuclei in a concentration-dependent manner, relative to HG-only treated cells.
-
Cell Line:CoCl2-injured human umbilical vein endothelial cells (HUVECs)
-
Concentration:5, 10 and 20 μM
-
Incubation Time:12 h
-
Result:Reduced the percentage of apoptotic HUVECs with condensed/fragmented nuclei in a concentration-dependent manner, relative to CoCl2-only treated cells.
-
Cell Line:ox-LDL-injured human umbilical vein endothelial cells (HUVECs)
-
Concentration:5, 10 and 20 μM
-
Incubation Time:6 h
-
Result:Concentration-dependently reduced the ox-LDL-induced upregulation of ICAM-1 and VCAM-1 protein levels, with greater efficacy than tBHQ.
-
Cell Line:high glucose (HG)-injured human umbilical vein endothelial cells (HUVECs)
-
Concentration:5, 10 and 20 μM
-
Incubation Time:24 h
-
Result:Concentration-dependently reduced the HG-induced upregulation of ICAM-1 and VCAM-1 protein levels, with greater efficacy than tBHQ.
-
Cell Line:CoCl2-injured human umbilical vein endothelial cells (HUVECs)
-
Concentration:5, 10 and 20 μM
-
Incubation Time:12 h
-
Result:Concentration-dependently reduced the CoCl2-induced upregulation of ICAM-1 and VCAM-1 protein levels, with greater efficacy than tBHQ.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, STZ-induced diabetes)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; daily; 8 weeks
-
Result:Significantly alleviated intimal damage and vascular fibrosis, with lower relative fibrosis severity compared to the STZ-only group.
Reduced the proportion of apoptotic cells in the thoracic aortic endothelium compared to the STZ-only group.
Decreased aortic tissue MDA and LPO content relative to the STZ-only group.
Increased aortic tissue GSH content relative to the STZ-only group.
Chemical Information
-
Molecular Weight 259.30
-
Formula C15H17NO3
-
SMILES
O=C(N1C=CC=C1)OC2=CC=C(O)C(C(C)(C)C)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz